Literature DB >> 18171600

Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells.

Hui Xing1, Danhui Weng, Gang Chen, Wenming Tao, Tao Zhu, Xiaokui Yang, Li Meng, Shixuan Wang, Yunping Lu, Ding Ma.   

Abstract

The purpose of this study was to investigate the possible role of PI-3K/Akt2 pathway in docetaxel-induced apoptosis. Here we showed that transfection of full-length Akt2 into breast and ovarian cancer cells could provoke Akt phosphorylation and induce an enhanced resistance to docetaxel. FN adhesion promoted Akt phosphorylation in highly metastatic cancer cells A2780 and MDAMB231, and further brought on significant protection for tumor cells against docetaxel-induced apoptosis. Inhibition of Akt2 activity by co-transfection with two shRNA vectors targeting the same Akt2 mRNA or simply by administration with PI 3-Kinase inhibitor Ly294002 counteracted the ability of FN to protect cells from undergoing apoptosis induced by docetaxel. We further showed that Akt2 activation protected against docetaxel-induced apoptosis by regulating survivin levels in a PI 3-Kinase-dependent manner. We conclude that FN/PI-3K/Akt2 pathway might play an important role in inducing resistance to docetaxel in breast and ovarian cancer cells. Our results therefore indicate that the activation of Akt2, promoted by FN attachment, might be critical in determining whether cells survive or undergo apoptosis. Targeting the PI-3K/Akt2 pathway might be a promising strategy for enhancing sensitivity to docetaxel in breast or ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18171600     DOI: 10.1016/j.canlet.2007.11.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  32 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

2.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

3.  Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.

Authors:  Majid Momeny; Reza Ghasemi; Giovanni Valenti; Mariska Miranda; Ali Zekri; Ghazaleh Zarrinrad; Sepehr Javadikooshesh; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Tumour Biol       Date:  2015-10-19

Review 4.  Tumor microenvironment promotes breast cancer chemoresistance.

Authors:  Umar Mehraj; Abid Hamid Dar; Nissar A Wani; Manzoor A Mir
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-09       Impact factor: 3.333

Review 5.  Diverse mechanisms of AKT pathway activation in human malignancy.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Curr Cancer Drug Targets       Date:  2013-03       Impact factor: 3.428

6.  Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Authors:  Stephanie N Dorman; Katherina Baranova; Joan H M Knoll; Brad L Urquhart; Gabriella Mariani; Maria Luisa Carcangiu; Peter K Rogan
Journal:  Mol Oncol       Date:  2015-08-22       Impact factor: 6.603

7.  BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.

Authors:  Francesco Crea; Maria A Duhagon Serrat; Elaine M Hurt; Suneetha B Thomas; Romano Danesi; William L Farrar
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

Review 8.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

9.  Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.

Authors:  Sida Qin; Boxiang Zhang; Guodong Xiao; Xin Sun; Gang Li; Guanghong Huang; Xiao Gao; Xiang Li; Huangzhen Wang; Chengcheng Yang; Hong Ren
Journal:  Tumour Biol       Date:  2016-07-28

10.  ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.

Authors:  Janine M Buonato; Matthew J Lazzara
Journal:  Cancer Res       Date:  2013-10-09       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.